MedPath

Dual Guidance in Regional Anesthesia

Not Applicable
Completed
Conditions
Anesthesia; Adverse Effect
Anesthesia, Local
Anesthesia
Registration Number
NCT03383770
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

Regional anaesthesia is a frequently used procedure. Currently, blockades are increasingly carried out without nerve stimulation. The risk of nerve lesion is about 3 %. Industrial efforts frequently referred to ultrasound optimisation of the regional anaesthesia cannula. In order to optimise patient safety, the benefit of both procedures (stimulation and ultrasound) should be combined and both procedures optimised. In this study, the influence of the needle electrode size on the stimulability of the nerve ischiadicus should be determined.

Detailed Description

There are various methods of performing regional anesthesia. In recent years, the focus has been on ultrasound-supported regional anaesthesia, and the stimulation methods that were often used in the past were no longer used or used less frequently. The combination of both methods may be an additional safety aspect and can contribute to an improved blocking quality. In addition to the best possible ultrasound quality, an optimal stimulation quality is also required. The investigators plan to carry out dual-guidance blockages of the ischiadic nerve with various regional anaesthesia needles (manufacturer of the used needles: Pajunk Medical Produkte GmbH, Geisingen, Germany; Teleflex Medical GmbH, Kernen, Germany). All regional anaesthesia cannulae are approved for the planned blockades of humans in Germany.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Presence of the written declaration of consent
  • Age of at least 18 years
  • No participation in another intervention study during participation
Exclusion Criteria
  • present contraindication for the application of regional anesthesia and nerve stimulation
  • Cardiac pacemaker/AICD (Automated internal cardioverter defibrillator) carrier
  • Known allergies to used medicines
  • Patients under 18 years of age
  • Ineligible patients
  • Missing consent
  • Pregnancy/nursing patients
  • Classification of patients into class 4 or higher status according to the American Society of Anesthesiologists
  • Existing nerve damage in the target area
  • Medically treated diabetes mellitus, alcohol abuse or alcohol abuse in the patient's history (using AUDIT)
  • Visibility score of the nerve of 3 or more
  • Participation in another intervention study during participation
  • Accommodation in an institution on the basis of a court or administrative order

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Ultrasound distanceduration of blockade, an average of 15 minutes

Ultrasound-based measurement of needle-nerve distance during the application of the regional anesthesia of the N. ischiadicus during infragluteal access.

Secondary Outcome Measures
NameTimeMethod
Visibility_1duration of blockade, an average of 15 minutes

Ultrasound visibility of needle

Impedanceduration of blockade, an average of 15 minutes

Impedance measured by nerve stimulator while progressing the needle

Visibility_2duration of blockade, an average of 15 minutes

Ultrasound visibility of nerve

Effect_sensoricduration of surgery and recovery unit, an average of 120 minutes

Effectiveness of the blockade measured by temperature sensibility testing on the food

Effect_motorduration of surgery and recovery unit, an average of 120 minutes

Effectiveness of the motor blockade measured by possible movement of the foot

Trial Locations

Locations (1)

Charité - Universitätsmedizin Berlin Campus Charité Mitte

🇩🇪

Berlin, Deutschland, Germany

Charité - Universitätsmedizin Berlin Campus Charité Mitte
🇩🇪Berlin, Deutschland, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.